Vital safety checks were not carried out on Covid vaccines before they were rolled out to millions, Germany’s pandemic ...

If approved by regulators, it could become the only Lyme disease vaccine available for people — although it would not be the ...

Pfizer Inc. (NYSE: PFE) today announced that it has received notice of an unsolicited mini-tender offer by Tutanota LLC ("Tutanota") to purchase up to 1 million shares of Pfizer common stock at a ...

This appointment reflects a shared mission with Lucid Group to transform lives by ensuring innovative medicine doesn't stop at approval but reaches the patients who need it most. His leadership marks ...

Pfizer markets 13 blockbuster drugs. Seven of them generated sales of over $2 billion last year. The company's pipeline ...

Pfizer Inc. is drawing on lessons learned years ago from rolling out Viagra as it maps out the launch of its first obesity medicine. The parallels between weight loss and erectile dysfunction — two ...

In the last six months Pfizer’s stock (NYSE: PFE) has underperformed Merck (NYSE: MRK) and Johnson & Johnson (NYSE: JNJ) primarily due to waning demand for its COVID-19 products, a significant ...

Pfizer remains a Strong Buy, with oncology breakthroughs, a revitalized obesity pipeline, and aggressive cost savings supporting a compelling value thesis. BRAFTOVI's Phase 3 success and PADCEV + ...

Pfizer Inc. enters 2026 facing earnings pressure from COVID revenue collapse and acquisition-related dilution, despite an aggressive strategic repositioning. The $10 billion Metsera acquisition ...

Pfizer Inc. (NYSE: PFE) disclosed the death of a participant in a long-term open-label extension study of marstacimab in patients with hemophilia A or B. In October 2024, the FDA approved Pfizer’s ...